IMTX trades 155.6% below Wall Street's consensus target of $25.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IMTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Immatics N.V. (IMTX) has a Wall Street consensus price target of $25.00, based on estimates from 8 covering analysts. With the stock currently trading at $9.78, this represents a potential upside of +155.6%. The company has a market capitalization of $1.31B.
Analyst price targets range from a low of $25.00 to a high of $25.00, representing a 0% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IMTX trades at a trailing P/E of -5.5x. Analysts expect EPS to grow -7.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
TCRTAlaunos Therapeutics, Inc. | $5M | $2.16 | — | — | — | — | — |
AGENAgenus Inc. | $127M | $3.04 | $7.33 | +144.3% | Buy | 3.8x | 11 |
FATEFate Therapeutics, Inc. | $251M | $2.15 | $5.50 | +163.2% | Buy | — | 31 |
CRISCuris, Inc. | $83M | $0.43 | — | — | Buy | — | 18 |
NKTXNkarta, Inc. | $200M | $2.79 | $9.00 | +214.7% | Buy | — | 12 |
KYMRKymera Therapeutics, Inc. | $8.1B | $99.45 | $112.60 | +24.5% | Buy | — | 26 |
RCUSArcus Biosciences, Inc. | $2.7B | $27.23 | $31.00 | +27.5% | Buy | — | 18 |
IMVTImmunovant, Inc. | $7.8B | $38.10 | $45.00 | +27.3% | Buy | — | 23 |
TGTXTG Therapeutics, Inc. | $8.3B | $54.40 | $54.50 | +2.4% | Buy | 38.6x | 13 |
MGNXMacroGenics, Inc. | $291M | $4.58 | $6.00 | +45.3% | Buy | — | 22 |
Quick answers to the most common questions about buying IMTX stock.
The consensus Wall Street price target for IMTX is $25, representing 155.6% upside from the current price of $9.78. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IMTX has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $25 implies 155.6% upside from current levels.
IMTX's current price is $9.78 with a consensus target of $25 (155.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $25 for IMTX, while the most conservative target is $25. The consensus of $25 represents the median expectation. These targets typically reflect 12-month expectations.
IMTX is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IMTX stock forecast based on 8 Wall Street analysts shows a consensus price target of $25, with estimates ranging from $25 (bear case) to $25 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IMTX, with a "Buy" consensus rating and $25 price target (155.6% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IMTX analyst price targets range from $25 to $25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.